Featured Research

from universities, journals, and other organizations

CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1

Date:
December 1, 2009
Source:
Duke University Medical Center
Summary:
Tests performed by the Centers for Disease Control and Prevention at the request of infectious disease experts have confirmedthat isolates from four patients with H1N1 influenza at Duke University Hospital during October and November were found to be resistant to oseltamivir (Tamiflu).

Tests performed by the Centers for Disease Control and Prevention (CDC) at the request of infectious disease experts at Duke University Medical Center have confirmedthat isolates from four patients with H1N1 influenza at Duke University Hospital over the past six weeks were found to be resistant to oseltamivir (Tamiflu).

Two oseltamivir-resistant H1N1 isolates were reported in western North Carolina earlier this summer.

A team of experts from CDC, State of North Carolina Public Health Department, Durham County Health Department, and the Duke Division of Infectious Diseases are now working collaboratively to better understand the nature of these cases.

All four isolates, or samples, were obtained from four patients in an isolated unit of one floor at Duke University Hospital. All four patients were very ill with underlying severely compromised immune systems and multiple other complex medical conditions.

"We're partnering with all of the involved agencies to examine these cases," said Daniel Sexton, MD, professor of medicine and director of the Duke Infection Control Outreach Network (DICON).

"Our extensive investigation thus far has revealed that appropriate infection control procedures have been diligently practiced on this isolated unit, and throughout the hospital, and we have experienced no illness among employees taking care of these patients in the affected unit over this period of time."

According to CDC, patients with oseltamivir-resistant H1N1 have had similar, no more severe, illness than patients with oseltamivir-susceptible virus.

Furthermore, CDC reports that all confirmed cases of oseltamivir-resistant virus to date have been susceptible to zanamivir (Relenza), a second antiviral medication that is indicated for the treatment of H1N1. At this time, CDC does not recommend any changes in antiviral guidance.

There is no evidence these few cases represent a hospital-wide concern. Furthermore, the number of hospitalizations at Duke for H1N1 influenza had declined in early November, consistent with new information recently released by the North Carolina State Department of Health that documents overall declines statewide in hospitalizations, emergency room visits, and other such measures.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1." ScienceDaily. ScienceDaily, 1 December 2009. <www.sciencedaily.com/releases/2009/11/091130121941.htm>.
Duke University Medical Center. (2009, December 1). CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/11/091130121941.htm
Duke University Medical Center. "CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1." ScienceDaily. www.sciencedaily.com/releases/2009/11/091130121941.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins